Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
Authors' conclusion
SGLT2 inhibitor prescription rates among Dutch adults with T2DM were low, with persistent age- and sex-related disparities independent of frailty, highlighting the need for equitable prescribing.
Study context
- Population
- Adults with T2D registered in Dutch primary care during 2023 (GIANTT database); SGLT2i eligibility per NHG guideline4,223 eligible
- Participants
- 10,241 adults
- Exposure
- SGLT2i prescription by age group
- Outcome
- SGLT2i prescription rate among eligible people, by age
- Follow-up
- 2023
Methodological detailsobservational, primary care database (GIANTT), multivariable logistic regression
- Observational
- Primary care database (GIANTT)
- Multivariable logistic regression
Main finding
As reported in the abstract
SGLT2i prescription rate among eligible people
Each group vs <60 yearsOdds ratio (95% CI)
70-79 years
0.56(0.43–0.72)
≥80 years
0.22(0.16–0.30)
Observational data: associations, not effects.
Further findings
SGLT2i prescription rate, overall and eligible populations
- Prescription rate, overall population
- 15.2%
- Prescription rate, eligible people
- 25.5%
Age disparities by sex and frailty subgroups
- Age disparities evident across frailty levels and both sexes, particularly pronounced in females vs males
- P for interaction = 0.01
- Females had lower prescription rates than males across age groups and frailty levels
Original publication
Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex. Diabetes Obes Metab. Published 2 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →